Lumiliximab
Lumiliximab (pronounced loo-mi-lixi-mab) is a monoclonal antibody designed for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). It is a biopharmaceutical product that was developed by Biogen Idec Inc.
Etymology
The name "Lumiliximab" is derived from the Latin word "lumen" meaning light, and "liximab" which is a common suffix for monoclonal antibodies.
Mechanism of Action
Lumiliximab works by binding to a specific protein, CD23, on the surface of B-cells. This binding triggers the immune system to destroy these cells, thereby reducing the number of cancerous cells in the body.
Clinical Trials
Lumiliximab has been tested in several clinical trials. In a Phase II trial, it was combined with fludarabine, cyclophosphamide, and rituximab (FCR) for the treatment of B-CLL. The results showed that the combination of Lumiliximab and FCR was well-tolerated and had a high response rate.
Related Terms
- Monoclonal Antibody
- B-cell Chronic Lymphocytic Leukemia
- Biopharmaceutical
- Clinical Trials
- Fludarabine
- Cyclophosphamide
- Rituximab
External links
- Medical encyclopedia article on Lumiliximab
- Wikipedia's article - Lumiliximab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski